Advancing RNA

ARW ON RNA

Success Transformation, improvement, leadership-GettyImages-1417761158

Beyond The Gold Standard(s): Modernizing Oligonucleotide Synthesis

A few weeks ago, I had the chance to sit down with OPT Congress speaker Phil Baran, Richard Lerner Chair Professor, Department of Chemistry, Scripps Research. Baran was slated to (and did) present a keynote on the innovations shaping the next generation of oligo synthesis. Here, I share the biggest takeaways I had from our conversation, touching on how he sees the science of oligo chemistry and manufacturing advancing in the near and far future.

OUR EXPERT NETWORK

Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.
Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos
Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.
From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics
Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.
5 Key Questions On How To Accelerate mRNA Development
Stakeholders are working to solve key mRNA manufacturing challenges, including how raw materials impact product quality and how to address scale up. Though existing analytical and manufacturing technologies may fall short for mRNA, investment in innovative techniques will help meet increasing demand for personalized therapeutics.
A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis
Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

WEBINARS

Advancing mRNA-LNP Delivery And Small-Scale Manufacturing, APAC Session

Unlocking The Next Wave Of Cancer Vaccines

Optimizing Antibody Variant Capture: Strategies To Combat Aggregation, Impurities, And Low Yields

Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

Your AKTA Oligosynt™ System : It's More Than A Machine

Take The Wheel And Drive Your Oligo Synthesis Where You Want

Five Practical Considerations To Move From Concept To Clinic

Hear From The Experts: LNPs Driving The Future Of Cell Therapy

MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.

Start the conversation by following me on LinkedIn!

RNA HOT TAKES

VIRTUAL EVENTS

More Virtual Events

NEWSLETTER ARCHIVE

More Newsletters